Clear cell carcinoma is a rare type of ovarian cancer with poor response to chemotherapy and few effective treatment options available in advanced and recurrent disease settings. The latest ovarian cancer clinical trials in immunotherapy – treatments that help the immune system fight cancer – have shown overall disappointing responses. However, further analyses of these studies show promise for immunotherapy as a potential treatment strategy for women with ovarian clear cell carcinoma. Reliable strategies to predict response to immunotherapy remain poorly understood. Deciphering the ovarian clear cell tumor profile through a series of cutting-edge analyses is critical to discovering treatment prediction markers.

The aim of this study is to define distinct profiles of ovarian clear cell carcinoma patients associated with: 1) good versus poor response to immunotherapy; 2) high treatment-related toxicities. This study will enable treatment personalization with the ultimate goal of improving patient outcomes in this rare and understudied cancer.